Predictors of time to publication of covid-19 trial preprints
| Median (95% CI) time to publication (days) | P value | |
| Funding | ||
| Industry funding (n=47) | 171 (145 to NA) | 0.72 |
| No industry funding (n=127) | 219 (177 to NA) | |
| Government funding (n=78) | 155 (120 to 192) | 0.02 |
| No government funding (n=96) | 309 (183 to NA) | |
| Institutional funding (n=58) | 136 (90 to NA) | 0.14 |
| No institutional funding (n=116) | 192 (166 to NA) | |
| Not-for-profit funding (n=26) | 110 (79 to NA) | 0.07 |
| No not-for-profit funding (n=148) | 188 (161 to NA) | |
| No of centres | ||
| Single centre (n=65) | Undefined (130 to undefined) | 0.13 |
| Multicentre (n=90) | 161 (136 to 219) | |
| No of participants | ||
| More than median (n=88) | 142 (120 to NA) | 0.14 |
| Less than median (n=85) | 219 (171 to NA) | |
| Intensity of care | ||
| Inpatient (n=122) | 110 (95 to 144) | <0.0001 |
| Outpatient (n=38) | Undefined | |
| Severity | ||
| Mild or moderate disease (n=79) | 182 (159 to 263) | 0.00001 |
| Severe or critical disease (n=42)37 | 101 (89 to 128) | |
| Early termination for benefit | NA | NA |
| Primary outcome significance | ||
| Significant (n=77) | 243 (155 to undefined) | 0.12 |
| Not significant (n=91) | 161 (127 to 219) | |
| Any secondary outcomes statistically significant | ||
| Significant (n=96) | 187 (120 to NA) | 0.66 |
| Not significant (n=64) | 152 (120 to NA) | |
| Risk of bias | ||
| Low (n=52) | 155 (124 to 187) | 0.17 |
| High (n=102) | 122 (98 to 161) | |
CI= confidence interval; NA=not available. Upper bounds of confidence intervals could often not be estimated owing to insufficient follow-up of preprints.